Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

NCT05920135 is registered in ClinicalTrials.gov with Bridge Biotherapeutics, Inc. as lead sponsor.

NCT NCT05920135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05920135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI
Lead sponsor
Bridge Biotherapeutics, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 11, 2023
Completion date
August 1, 2028
Enrollment
24 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

egfr mutant advanced non-small cell lung cancer